Bristol-Myers Squibb: Devens, Massachusetts
Our Company Home
Our Mission & Commitment
Compliance & Ethics
Diversity & Inclusion
In the Pipeline
Investigational Compound News
R&D Areas of Focus
Major R&D Facilities
Expanded Access to Investigational Medicines
Investigator- Sponsored Research
Help Paying For Your Medicine
Medical Information Inquiries
Subscribe to e-mail alerts
Dividends & Splits
News & Events
Why Partner With Us?
Areas of Interest
Ensuring Success through Alliance Management
Bristol-Myers Squibb Foundation
Help Paying For Your Medicine
Building Our Communities
Grants & Giving
Position on Key Issues
Combating Counterfeit Drugs
Disaster Relief & Product Donations
Access to Medicines
Diversity & Inclusion
Field Medical Opportunities
Developing Our People
Military Veterans Resources
NEW Tampa Jobs
Responsibility Message from CEO
About this GRI Report
Sustainability Goals and Key Indicators
Redwood City, California
Bloomsbury, New Jersey
Hopewell, New Jersey
Nassau Park, New Jersey
New Brunswick, New Jersey
Plainsboro, New Jersey
Princeton, New Jersey
New York City, New York
Syracuse, New York
Humacao, Puerto Rico
Manati, Puerto Rico
Governance and Management
Facts and Figures
Located 45 miles west of Boston, the 89-acre site accommodates a large-scale bulk biologics facility. The site currently includes four main buildings: a BioPharma manufacturing facility, a central utility building, an administrative/quality control building and a warehouse/storage structure. Another building houses the site’s process waste water pretreatment plant.
The facility supports the production of ORENCIA® (abatacept), the company's biologic therapy for rheumatoid arthritis.
Phase II of construction began in January of 2014 and will introduce biologics development and clinical trial manufacturing capabilities to the site. The two buildings that are part of Phase II of construction will double the built square footage, adding approximately 200,000 square feet of laboratory and office space to the Devens site. Approximately 350 employees will be added to the Devens workforce over time.
Devens phase I construction was completed in 2009. It was Bristol-Myers Squibb’s largest capital investment in its history – $750 million – and helped signal the company’s transformation into a next-generation biopharmaceutical company.
Phase II of construction will represent an additional capital investment of approximately $250 million. Construction is expected to be completed in late 2015.
Community and Social Progress
The Devens Facility supported Ayer Public School System Science Program
BMS Devens employees supported a local shelter than runs a housing facility for women with children in Devens, MA.
BMS Devens employees routinely donate their time at a food pantry that serves local communities.
The Devens Facility conducts clothing drives to aid homeless US veterans as a regular part of site community outreach activities.
The Devens Facility partners with MassBio Ed’s job shadow program to introduce area high school students to the biotech industry.
Bristol-Myers Squibb was awarded Leadership in Energy and Environmental Design (LEED) Gold certification for the laboratory / administration building and LEED Silver certification for the cell culture manufacturing facility. The new clinical development and biologics development buildings are being constructed to meet LEED Silver standards. LEED is a recognized certification program administered by U.S. Green Buildings Council (www.USGBC.org). Certification is based on many project design aspects, including site development, environmental impact, water and energy use, construction impact, and architectural and building materials.
The Devens site was awarded with an innovation award by the Massachusetts Toxic Use Reduction Institute (TURI) for a project that recycled 3.6 million gallons of clean and flush water associated with facility startup.
The site is an active partner with EcoStar, a local non-profit organization that works with companies to develop and enhance various environmental, health and safety operational practices.
The facility adopted the Blanding Turtle ("threatened" under the Massachusetts Endangered Species Act) as part of the company's Sustainability goals, which encourage each facility and business to help protect endangered species and habitats. To protect the turtles, Devens employees developed a partnership with the Commonwealth of Massachusetts Department of Fish and Game, the U.S. Fish & Wildlife service and local conservation groups, through which BMS employees have participated in events to preserve the breeding areas for these turtles.
Devens employees have partnered with local conservation groups by engaging in invasive plant removal in local streams and ponds, as well as by maintaining sections of local walking trails.
Facility Contact Information
© 2015 Bristol-Myers Squibb Company
You are leaving BMS.com to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.